These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 9119123)

  • 61. The removal of viruses during the purification of equine antisera using filtration aids Hyflo Super-Cel and Fulmon Super A.
    Cameron-Smith R; Miloradovic L; Cheyne I; Healy K
    Biologicals; 2000 Sep; 28(3):169-74. PubMed ID: 10964443
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Analysis of viral clearance unit operations for monoclonal antibodies.
    Miesegaes G; Lute S; Brorson K
    Biotechnol Bioeng; 2010 Jun; 106(2):238-46. PubMed ID: 20073086
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Human retroviruses and herpesviruses: problems and solutions in safety testing of biologicals.
    Onions D; Lees G
    Dev Biol Stand; 1991; 75():145-58. PubMed ID: 1794616
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Viral safety of biological products and the concept of validation.
    Horaud F
    Dev Biol Stand; 1996; 88():19-24. PubMed ID: 9119135
    [No Abstract]   [Full Text] [Related]  

  • 65. Viral clearance using disposable systems in monoclonal antibody commercial downstream processing.
    Zhou JX; Solamo F; Hong T; Shearer M; Tressel T
    Biotechnol Bioeng; 2008 Jun; 100(3):488-96. PubMed ID: 18438883
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Safety assurance for biologics manufactured in mammalian cell cultures: a multitiered strategy.
    Chen D
    Adv Biochem Eng Biotechnol; 2014; 139():167-83. PubMed ID: 23719711
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Safety characterization of HeLa-based cell substrates used in the manufacture of a recombinant adeno-associated virus-HIV vaccine.
    Tatalick LM; Gerard CJ; Takeya R; Price DN; Thorne BA; Wyatt LM; Anklesaria P
    Vaccine; 2005 Apr; 23(20):2628-38. PubMed ID: 15780446
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim.
    Banton D; Vacante D; Bulthuis B; Goldstein J; Wineburg M; Schreffler J
    PDA J Pharm Sci Technol; 2019; 73(6):552-561. PubMed ID: 31101710
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Inactivation of enveloped and non-enveloped viruses in the process of chemical treatment and gamma irradiation of bovine-derived grafting materials.
    Lee KI; Lee JS; Jung HH; Lee HY; Moon SH; Kang KT; Shim YB; Jang JW
    Xenotransplantation; 2012; 19(6):365-9. PubMed ID: 23198732
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
    Goldsmith JC
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Photochemical decontamination of red blood cell concentrates with the silicon phthalocyanine PC 4 and red light.
    Ben-Hur E; Chan WS; Yim Z; Zuk MM; Dayal V; Roth N; Heldman E; Lazo A; Valeri CR; Horowitz B
    Dev Biol (Basel); 2000; 102():149-55. PubMed ID: 10794102
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Real time quantitative PCR as a method to evaluate xenotropic murine leukemia virus removal during pharmaceutical protein purification.
    Shi L; Chen Q; Norling LA; Lau AS; Krejci S; Xu Y
    Biotechnol Bioeng; 2004 Sep; 87(7):884-96. PubMed ID: 15334415
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cell banking.
    Wiebe ME; May LH
    Bioprocess Technol; 1990; 10():147-60. PubMed ID: 1367056
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Viral inactivation of intramuscular immune serum globulins.
    Alonso WR; Trukawinski S; Savage M; Tenold RA; Hammond DJ
    Biologicals; 2000 Mar; 28(1):5-15. PubMed ID: 10799050
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A review of clinical studies evaluating the efficacy of HIV inactivation methods.
    Lawrence DN
    Prog Clin Biol Res; 1990; 324():151-60. PubMed ID: 2308967
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Relationship between nature and source of risk and process validation.
    Berthold W; Werz W; Walter JK
    Dev Biol Stand; 1996; 88():59-71. PubMed ID: 9119164
    [No Abstract]   [Full Text] [Related]  

  • 77. Characterization of gene therapy products and the impact of manufacturing changes on product comparability.
    Simek SL
    Dev Biol (Basel); 2005; 122():139-44. PubMed ID: 16375258
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
    Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
    Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Development of serum-free media for cell growth and production of viruses/viral vaccines--safety issues of animal products used in serum-free media.
    Merten OW
    Dev Biol (Basel); 2002; 111():233-57. PubMed ID: 12678248
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Generic/matrix evaluation of SV40 clearance by anion exchange chromatography in flow-through mode.
    Curtis S; Lee K; Blank GS; Brorson K; Xu Y
    Biotechnol Bioeng; 2003 Oct; 84(2):179-86. PubMed ID: 12966574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.